Guizhou Xinbang Pharmaceutical News

Xinbang Pharmaceutical (002390) Company Brief Review Report: Steady overall operation and rapid release of Chinese medicine tablets

東海證券Apr 19 19:41

Donghai Securities released a research report on April 19 stating that it gave Xinbang Pharmaceuticals (002390.SZ) a purchase rating. The main reasons for the rating include: 1) rapid profit growth and continuous improvement in cash flow; 2) medical servi

Zhitong FinanceApr 19 18:27

Xinbang Pharmaceutical (002390) Company In-depth Report: Regional Medical Leaders Collaborate to Develop and Improve the Whole Industry Chain

東海證券Dec 29, 2023 00:00

Xinbang Pharmaceutical (002390): Steady improvement in business quality, new production capacity brings additional volume

上海證券Nov 2, 2023 20:42

Xinbang Pharmaceutical (002390): Short-term pressure on medical services continues to release Chinese medicine tablets

西南證券Sep 7, 2023 18:32

Shinbang Pharmaceutical (002390): Performance is in line with expectations and is optimistic about annual growth

上海證券Sep 4, 2023 00:00

Xinbang Pharmaceutical (002390): The southwest's famous medical service group can be expected to collaborate in multiple sectors in the future

上海證券Aug 22, 2023 00:00

Xinbang Pharmaceutical (002390): Performance was affected by the pandemic and the Chinese medicine tablet business grew against the trend

西南證券Apr 22, 2023 00:00

Xinbang Pharmaceutical (002390): 2022 performance is under pressure and recovery in 2023 can be expected

天風證券Apr 20, 2023 07:22

Xinbang Pharmaceutical (002390) Company Information Update Report: Bad Factors Are Gradually Clear, Optimistic for Restorative Growth in 2023

開源證券Apr 18, 2023 13:50

Xinbang Pharmaceutical (002390): Performance was put under short-term pressure due to the epidemic, and the gradual restoration of traditional Chinese medicine tablets after the epidemic achieved rapid growth

東吳證券Apr 18, 2023 11:37

Xinbang Pharmaceutical (002390): Q3 performance is under pressure due to the epidemic and is optimistic about subsequent restorative growth

開源證券Nov 1, 2022 00:00

Xinbang Pharmaceutical (002390): Performance affected by the epidemic under pressure, traditional Chinese medicine tablets maintained high growth

天風證券Sep 3, 2022 00:00

Xinbang Pharmaceutical (002390): Cancer Hospitals' Net Interest Rates Increase, Traditional Chinese Medicine Tablet Revenue Is Growing Rapidly

西南證券Aug 27, 2022 00:00

Xinbang Pharmaceutical (002390): Cancer hospital profit margins increased month-on-month in a single quarter, Chinese medicine tablets achieved rapid growth

東吳證券Aug 26, 2022 15:11

Xinbang Pharmaceutical (002390): Affected by the epidemic, performance is pressured, and profit acceleration in the third quarter can be expected

開源證券Aug 26, 2022 13:47

Xinbang Pharmaceutical (002390): Regional Medical Service Industry Leaders and Multiple Sectors Collaborate to Achieve Good Results

西南證券Jun 14, 2022 00:00

Xinbang Pharmaceutical (002390): 1Q22 is basically in line with expectations, and hospital management is expected to continue to be optimized

中金公司May 5, 2022 00:00

Xinbang Pharmaceutical (002390) 2021 Report Review: Steady Revenue Growth, Increased Profit Margins for Cancer Hospitals

東吳證券Apr 15, 2022 19:11

Xinbang Pharmaceutical (002390) Company Information Update Report: Performance Growth Meets Expectations Continued Improvement in Hospital Operations

開源證券Jan 25, 2022 00:00